Skip to main content

Advertisement

SpringerLink
Log in

Ru-106 plaque radiotherapy for vasoproliferative tumors of retina: a 15-year single-center experience

  • Original Paper
  • Published:
International Ophthalmology Aims and scope Submit manuscript

Abstract

Purpose

This study evaluates the outcomes of ruthenium-106 (Ru-106) plaque brachytherapy for vasoproliferative tumors (VPTs) of the ocular fundus in a single referral ocular oncology center.

Methods

The clinical charts of all patients diagnosed with VPT who underwent plaque radiotherapy from 2002 to 2017 were reviewed. Clinical features, types of treatment, outcomes and complications were evaluated.

Results

Of 46 patients with VPT diagnosis in our ocular oncology clinic, 25 (54.34%) cases were treated with Ru-106 plaque brachytherapy. Eleven patients (44%) were male, and the mean age at the time of diagnosis was 40.92 ± 13.11 years. The mean follow-up time was 47.56 ± 36.87 months. Inferotemporal quadrant was the most common site of the tumor (64.00%). The mean delivered apex and scleral dose was 101.56 ± 6.51 and 412.26 ± 113.66 Gray (Gy), respectively. Initial tumor length, width and thickness were 10.26 ± 3.42, 8.05 ± 2.83 and 4.27 ± 1.10 mm, respectively. The mean tumor thickness decreased to 2.60 ± 0.63 mm, postoperatively. Complete resolution of subretinal fluid around the tumor was achieved in 81.80% of cases. Visual acuity was more than 20/400 in 64% of patients before treatment and 60% of patients at last follow-up.

Conclusion

Our study showed that Ru-106 plaque radiotherapy is an effective and safe method of treatment in VPTs.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Baines PS, Hiscott PS, McLeod D (1982) Posterior nonvascularized proliferative extraretinopathy and peripheral nodular retinal telangiectasis. Trans Ophthalmol Soc UK 102:487–491

    PubMed  Google Scholar 

  2. Shields CL, Shields JA, Barrett J, De Potter P (1995) Vasoproliferative tumors of the ocular fundus: classification and clinical manifestations in 103 patients. Arch Ophthalmol 113(5):615–623

    Article  CAS  Google Scholar 

  3. Rennie IG (2010) Retinal vasoproliferative tumours. Eye (Lond) 24(3):468–471. https://doi.org/10.1038/eye.2009.305

    Article  CAS  Google Scholar 

  4. Heinman H, Bornfeld N, Vij O et al (2000) Vasoproliferative tumors of retina. Br J Ophthalmol 84:1162–1169. https://doi.org/10.1136/bjo.84.10.1162

    Article  Google Scholar 

  5. Jain K, Berger AR, Yucil YH, McGowan HD (2003) Vasoproliferative tumors of retina. Eye (Lond) 17:364–368

    Article  CAS  Google Scholar 

  6. Brockmann C, Rehak M, Heufelder J et al (2016) Predictors of treatment response of vasoproliferative retinal tumors to ruthenium-106 brachytherapy. Retina Dec 36(12):2384–2390

    Article  CAS  Google Scholar 

  7. Naseripour M, Nazari H, Bakhtiari P et al (2009) Ruthenium-106 plaque radiotherapy for retinal vasoproliferative tumors. Iran J Ophthalmol 21(2):31–35

    Google Scholar 

  8. Shields CL, Kaliki S, Al-Dahmash S et al (2013) Retinal vasoproliferative tumors comparative clinical features of primary vs secondary tumors in 334 cases. JAMA Ophthalmol 131(3):328–334. https://doi.org/10.1001/2013.jamaophthalmol.524

    Article  PubMed  Google Scholar 

  9. Wachtlin J, Heimann H, Jandeck C et al (2002) Bilateral vasoproliferative retinal tumors with identical localization in a pair of monozygotic twins. Arch Ophthalmol 120(6):860–862

    PubMed  Google Scholar 

  10. Rundle P, Shields JA, Shields CL et al (2000) Vasoproliferative tumour of the ocular fundus associated with Waardenburg’s syndrome. Eye (Lond) 14:105–106

    Article  Google Scholar 

  11. Hood CT, Janku L, Lowder CY, Singh AD (2009) Retinal vasoproliferative tumor in association with neurofibromatosis type 1. J Pediatr Ophthalmol Strabismus. https://doi.org/10.3928/01913913-20090616-05

    Article  PubMed  Google Scholar 

  12. Damato B (2006) Vasoproliferative retinal tumour. Br J Ophthalmol 90:399–400. https://doi.org/10.1136/bjo.2005.086066

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Smith J, Steel D (2011) The surgical management of vasoproliferative tumours. Ophthalmologica 226(suppl 1):42–45. https://doi.org/10.1159/000328209

    Article  PubMed  Google Scholar 

  14. Cohen VML, Shields CL, Demirci H, Shields JA (2008) Iodine I 125 plaque radiotherapy for vasoproliferative tumors of the retina in 30 eyes. Arch Ophthalmol 126(9):1245–1251. https://doi.org/10.1001/archopht.126.9.1245

    Article  PubMed  Google Scholar 

  15. Irvine F, O’Donnell N, Kemp E, Lee WR (2000) Retinal vasoproliferative tumors: surgical management and histological findings. Arch Ophthalmol 118(4):563–569

    Article  CAS  Google Scholar 

  16. Heimann H, Bornfeld N, Vij O et al (2000) Vasoproliferative tumours of the retina. Br JOphthalmol. 84(10):1162–1169. https://doi.org/10.1136/bjo.84.10.1162

    Article  CAS  Google Scholar 

  17. Smeets MH, Mooy CM, Baarsma GS et al (1998) Histopathology of a vasoproliferative tumor of the ocular fundus. Retina 18(5):470–472

    Article  CAS  Google Scholar 

  18. Shields JA, Shields CL (1999) Vasoproliferative tumors of the ocular fundus. Atlas of intraocular tumors. Lippincott Williams & Wilkins, Philadelphia

    Google Scholar 

  19. Laqua H, Wessing A (1983) Peripheral retinal telangiectasis in adults simulating a vascular tumor or melanoma. Ophthalmology 90:1284–1291

    Article  CAS  Google Scholar 

  20. Kenway N, Groenwald C, Damato B (2007) Treatment of a vasoproliferative tumor with intravitreal Bevacizumab (Avastin). A case report. Presented in ISOO meeting 2007 Siena, Italy

  21. Anastassiou G, Bornfeld N, Schueler AO et al (2006) Ruthenium-106 plaque brachytherapy for symptomatic vasoproliferative tumors of the retina. Br J Ophthalmol 90:447–450. https://doi.org/10.1136/bjo.2005.081422

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. McDonald HR, Schatz H, Johnson RN et al (1996) Vitrectomy in eyes with peripheral retinal angioma associated with tractional macular detachment. Ophthalmology 103(2):329–335 (discussion 334-5)

    Article  CAS  Google Scholar 

  23. McCabe CM, Mieler WF (1996) Six-year follow-up of an idiopathic retinal vasoproliferative tumor. Arch Ophthalmol 114:617

    Article  CAS  Google Scholar 

  24. Medlock RD, Shields JA, Shields CL et al (1990) Retinal hemangioma-like lesions in eyes with retinitis pigmentosa. Retina 10(4):274–277

    Article  CAS  Google Scholar 

  25. Osman SA, Aylin Y, Arikan G et al (2007) Photodynamic treatment of a secondary vasoproliferative tumour associated with sector retinitis pigmentosa and Usher syndrome type I. Clin Exp Ophthalmology 35(2):191–193

    Article  Google Scholar 

  26. Barbezetto IA, Smith RT (2003) Vasoproliferative tumor of the retina treated with PDT. Retina 23:565–567

    Article  Google Scholar 

  27. Saldanha MJ, Edrich C (2008) Treatment of vasoproliferative tumors with photodynamic therapy. Ophthalmic Surg Lasers Imaging 39(2):143–145. https://doi.org/10.3928/15428877-20080301-13

    Article  PubMed  Google Scholar 

  28. Japiassu RM, Brasil OFM, Cunha AL et al (2008) Regression of vasoproliferative tumor with systemic infliximab. Ophthalmic Surg Lasers Imaging 39(4):348–349

    Article  Google Scholar 

  29. Shields CL, Naseripour M, Cater J et al (2002) Plaque radiotherapy for large posterior uveal melanomas (or = 8-mmthick) in 354 consecutive patients. Ophthalmology 109(10):1838–1849

    Article  Google Scholar 

  30. Forster MH, Bornfeld N, Schulz U et al (1986) Complications of local beta radiation of uveal melanomas. Graefe’s Arch Clin Exp ophthalmol 224:336–340

    Article  Google Scholar 

  31. Naseripour M, Jaberi R, Sedaghat A et al (2016) Ruthenium-106 brachytherapy for thick uveal melanoma: reappraisal of apex and base dose radiation and dose rate. J Contemp Brachytherapy 8(1):66–73. https://doi.org/10.5114/jcb.2016.57818

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Funding

This study is supported by the Eye Research Center, Rassoul Akram Hospital, Iran University of Medical Sciences, Tehran, Iran.

Author information

Authors and Affiliations

  1. Eye Research Center, Rassoul Akram Hospital, Iran University of Medical Sciences, Sattarkhan-Niayesh Street, Tehran, 14456-13131, Iran

    Navid Abolfathzadeh, Masood Naseripour, Sayyed Amirpooya Alemzadeh & Ahad Sedaghat

  2. Nikookari Eye Hospital, Tabriz University of Medical Sciences, Tabriz, Iran

    Navid Abolfathzadeh

  3. Cancer Institute, Imam Khomeini Hospital, Tehran University of Medical Sciences, Tehran, Iran

    Ramin Jaberi

  4. Radiation Medicine Department, Shahid Beheshti University, Tehran, Iran

    Zohreh Azma

  5. Radiation Oncology Department, Indiana University, Indiana, USA

    Mona Arbab

Authors
  1. Navid Abolfathzadeh
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Masood Naseripour
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ramin Jaberi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Zohreh Azma
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Sayyed Amirpooya Alemzadeh
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Mona Arbab
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Ahad Sedaghat
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ahad Sedaghat.

Ethics declarations

Conflict of interest

The authors have no conflict of interest in the materials used in this study.

Ethical approval

The study was conducted according to the tenets of the Declaration of Helsinki. The ethics committee of Iran University of Medical Sciences approved this retrospective study.

Informed consent

Informed consent for the treatment protocol and the data collection was obtained from all of the eligible patients.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Abolfathzadeh, N., Naseripour, M., Jaberi, R. et al. Ru-106 plaque radiotherapy for vasoproliferative tumors of retina: a 15-year single-center experience. Int Ophthalmol 40, 2095–2102 (2020). https://doi.org/10.1007/s10792-020-01386-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10792-020-01386-5

Keywords

Search

Navigation